Allergan warns Valeant bid would hit R&D

[at Financial Times] – Allergan has launched a robust defence against a near-$50bn bid by rival drugmaker Valeant and activist investor Bill Ackman, warning that a takeover would crush research and severely impair its ability … more

View todays social media effects on BAC

View the latest stocks trending across Twitter. Click to view dashboard

See who Bank is hiring next, click here to view